Skip to main content
SpringerLink
Log in

Enoxaparin cost effective after non-orthopaedic surgery in China

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Sanofi China.

Reference

  • Bao Y, et al. A Caprini Risk Score-Based Cost-Effectiveness Analysis of Enoxaparin for the Thromboprophylaxis of Patients After Nonorthopedic Surgery in a Chinese Healthcare Setting. Clinical Drug Investigation : 26 Nov 2019. Available from: URL: https://doi.org/10.1007/s40261-019-00876-4

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Enoxaparin cost effective after non-orthopaedic surgery in China. PharmacoEcon Outcomes News 843, 16 (2019). https://doi.org/10.1007/s40274-019-6443-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6443-z

Search

Navigation